Trethera COO Cary Talbot presents “The Waterfall,” the company’s structured product development strategy for TRE-515. This narrated presentation explains how a single drug candidate can support multiple development paths and generate unique revenue streams.
Topics covered include:
- TRE-515 as a monotherapy or in combination for solid tumors
- Opportunities in oncology and autoimmune disease indications
- Strategic milestones and checkpoints across the development lifecycle
- Trethera’s vision for translating science into marketable therapies
This session provides an inside look at how Trethera is driving innovation, managing risk, and positioning TRE-515 for multiple therapeutic opportunities.